Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromobenzene SCHEMBL28699914 | 0.91 | HTT (0.82) | HTTFGFR1 | |
| SCHEMBL3419279 | 0.90 | HTT (0.88) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| SCHEMBL30402227 | 0.90 | HTT (0.88) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| SCHEMBL2531256 | 0.85 | HTT (0.78) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| Benzene SCHEMBL14876970 | 0.84 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL157265 | 0.84 | HTT (1.00) | HTTFGFR1 | |
| SCHEMBL23243817 | 0.84 | HTT (0.65) | HTTFGFR1 | |
| SCHEMBL30892592 | 0.84 | HTT (0.65) | HTTFGFR1 | |
| SCHEMBL5246440 | 0.83 | HTT (0.75) | HTTFGFR1KDM4EALDH1A1RAB9A | |
| Iodide SCHEMBL30645138 | 0.82 | HTT (0.96) | HTTFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114989094-B | Method for synthesizing benzimidazole derivative by visible light catalysis | 云南民族大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-114989094-A | Method for synthesizing benzimidazole derivative by visible light catalysis | 云南民族大学 | 2022-09-02 | — | — | CN | disclosed |
| US-10651399-B2 | Delayed fluorescence compound, and organic light emitting diode and display device using the same | LG DISPLAY CO., LTD. (KR) | 2020-05-12 | — | — | US | disclosed |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3514147-A1 | STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | University of Maryland, Baltimore (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190036035-A1 | Delayed Fluorescence Compound, and Organic Light Emitting Diode and Display Device Using the Same | LG DISPLAY CO., LTD. (KR) | 2019-01-31 | — | — | US | disclosed |
| US-10193085-B2 | Delayed fluorescence compound, and organic light emitting diode and display device using the same | LG DISPLAY CO., LTD. (KR) | 2019-01-29 | — | — | US | disclosed |
| US-20180205023-A1 | Delayed Fluorescence Compound, and Organic Light Emitting Diode and Display Device Using the Same | LG DISPLAY CO., LTD. (KR) | 2018-07-19 | — | — | US | disclosed |
| US-20180205023-A1 | Delayed Fluorescence Compound, and Organic Light Emitting Diode and Display Device Using the Same | LG DISPLAY CO., LTD. (KR) | 2018-07-19 | — | — | US | disclosed |
| EP-2565185-A1 | [5,6]HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-31 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2170875-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HTT 775/4885FGFR1 2784/4885KDM4E 2778/4885 |
| US-10193085-B2 | Delayed fluorescence compound, and organic light emitting diode and display device using the same | OCIAD1, OCIAD2, OGFOD1 | HTT 1868/4885FGFR1 689/4885KDM4E 3098/4885 |
| US-20130029964-A1 | [5, 6] HETEROCYCLIC COMPOUND | BMP2, BMP4, SOST | HTT 4682/4885FGFR1 128/4885KDM4E 1999/4885 |
| US-10651399-B2 | Delayed fluorescence compound, and organic light emitting diode and display device using the same | OCIAD1, OCIAD2, DRD2 | HTT 705/4885FGFR1 1988/4885KDM4E 2711/4885 |
| US-10617685-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | AR, NR5A1, BRCA1 | HTT 1667/4885FGFR1 1290/4885KDM4E 1575/4885 |
| US-20190036035-A1 | Delayed Fluorescence Compound, and Organic Light Emitting Diode and Display Device Using the Same | OCIAD1, OCIAD2, DRD2 | HTT 705/4885FGFR1 1988/4885KDM4E 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.